Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples